These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 33258517)
1. Impact of mind-body treatment interventions on quality of life in neurofibromatosis patients: A systematic review and meta-analysis. Wei G; Farooq J; Kumar A Dermatol Ther; 2021 Jan; 34(1):e14613. PubMed ID: 33258517 [TBL] [Abstract][Full Text] [Related]
2. The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study. Vranceanu AM; Merker VL; Plotkin SR; Park ER J Neurooncol; 2014 Oct; 120(1):103-9. PubMed ID: 25022450 [TBL] [Abstract][Full Text] [Related]
3. Improvement in resiliency factors among adolescents with neurofibromatosis who participate in a virtual mind-body group program. Lester EG; Macklin EA; Plotkin S; Vranceanu AM J Neurooncol; 2020 Apr; 147(2):451-457. PubMed ID: 32078086 [TBL] [Abstract][Full Text] [Related]
4. Mind-body therapy via videoconferencing in patients with neurofibromatosis: An RCT. Vranceanu AM; Riklin E; Merker VL; Macklin EA; Park ER; Plotkin SR Neurology; 2016 Aug; 87(8):806-14. PubMed ID: 27449066 [TBL] [Abstract][Full Text] [Related]
5. Mind-Body Therapy via Videoconferencing in Patients With Neurofibromatosis: Analyses of 1-Year Follow-up. Lester EG; Gates MV; Vranceanu AM Ann Behav Med; 2021 Feb; 55(1):77-81. PubMed ID: 32421171 [TBL] [Abstract][Full Text] [Related]
6. Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial. Vranceanu AM; Manglani HR; Choukas NR; Kanaya MR; Lester E; Zale EL; Plotkin SR; Jordan J; Macklin E; Bakhshaie J JAMA Netw Open; 2023 Jun; 6(6):e2320599. PubMed ID: 37378983 [TBL] [Abstract][Full Text] [Related]
7. Psychological resiliency explains the relationship between emotional distress and quality of life in neurofibromatosis. Mace RA; Doorley J; Bakhshaie J; Cohen JE; Vranceanu AM J Neurooncol; 2021 Nov; 155(2):125-132. PubMed ID: 34570301 [TBL] [Abstract][Full Text] [Related]
8. The impact of a mind-body program on multiple dimensions of resiliency among geographically diverse patients with neurofibromatosis. Zale EL; Pierre-Louis C; Macklin EA; Riklin E; Vranceanu AM J Neurooncol; 2018 Apr; 137(2):321-329. PubMed ID: 29275505 [TBL] [Abstract][Full Text] [Related]
9. The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial. Presciutti AM; Lester EG; Woodworth EC; Greenberg J; Bakhshaie J; Hooker JE; McDermott KA; Vranceanu AM J Neurooncol; 2023 Jul; 163(3):707-716. PubMed ID: 37440099 [TBL] [Abstract][Full Text] [Related]
10. Baseline characteristics of adults with neurofibromatosis enrolled on a psychosocial randomized controlled trial. Fishbein NS; Vranceanu AM; Mace RA J Neurooncol; 2022 Sep; 159(3):637-646. PubMed ID: 35925531 [TBL] [Abstract][Full Text] [Related]
11. Virtual mind-body treatment for geographically diverse youth with neurofibromatosis: A pilot randomized controlled trial. Lester E; DiStefano S; Mace R; Macklin E; Plotkin S; Vranceanu AM Gen Hosp Psychiatry; 2020; 62():72-78. PubMed ID: 31841875 [TBL] [Abstract][Full Text] [Related]
13. Mind-Body Treatment for International English-Speaking Adults With Neurofibromatosis via Live Videoconferencing: Protocol for a Single-Blind Randomized Controlled Trial. Vranceanu AM; Zale EL; Funes CJ; Macklin EA; McCurley J; Park ER; Jordan JT; Lin A; Plotkin SR JMIR Res Protoc; 2018 Oct; 7(10):e11008. PubMed ID: 30355560 [TBL] [Abstract][Full Text] [Related]
14. First report of quality of life in adults with neurofibromatosis 2 who are deafened or have significant hearing loss: results of a live-video randomized control trial. Funes CJ; Mace RA; Macklin EA; Plotkin SR; Jordan JT; Vranceanu AM J Neurooncol; 2019 Jul; 143(3):505-513. PubMed ID: 31049826 [TBL] [Abstract][Full Text] [Related]
15. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. Vranceanu AM; Merker VL; Park E; Plotkin SR J Neurooncol; 2013 Sep; 114(3):257-62. PubMed ID: 23817811 [TBL] [Abstract][Full Text] [Related]
16. Diverse learners: learning disabilities and quality of life following mind-body and health education interventions for adults with neurofibromatosis. Kanaya MR; Greenberg J; Bakhshaie J; Vranceanu AM J Neurooncol; 2024 Apr; 167(2):315-322. PubMed ID: 38409461 [TBL] [Abstract][Full Text] [Related]
17. Minimal clinically important difference in the World Health Organization Quality of Life Brief (WHOQOL-BREF) for adults with neurofibromatosis. Pietrzykowski MO; Vranceanu AM; Macklin EA; Mace RA Qual Life Res; 2024 May; 33(5):1233-1240. PubMed ID: 38214851 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of QoL in neurofibromatosis patients: a systematic review and meta-analysis study. Sanagoo A; Jouybari L; Koohi F; Sayehmiri F BMC Neurol; 2019 Jun; 19(1):123. PubMed ID: 31189476 [TBL] [Abstract][Full Text] [Related]
19. Home practice and quality of life among patients with neurofibromatosis randomized to a mind-body intervention. Funes CJ; Zale EL; Luberto CM; Vranceanu AM Complement Ther Med; 2019 Feb; 42():114-118. PubMed ID: 30670227 [TBL] [Abstract][Full Text] [Related]
20. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. Merker VL; Bredella MA; Cai W; Kassarjian A; Harris GJ; Muzikansky A; Nguyen R; Mautner VF; Plotkin SR Am J Med Genet A; 2014 Jun; 164A(6):1431-7. PubMed ID: 24664633 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]